Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 2/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616322 | 0.93 | GBA1 (0.43) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL1616499 | 0.87 | AURKA (0.46) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL2917052 | 0.87 | AURKA (0.46) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL1616235 | 0.87 | GBA1 (0.44) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL1616089 | 0.85 | GBA1 (0.42) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL1616091 | 0.85 | GBA1 (0.42) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL2244198 | 0.83 | AURKA (0.46) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL1616236 | 0.82 | AURKA (0.45) | GBA1AURKARPS6KB1JAK2JAK1 | |
| SCHEMBL2245619 | 0.81 | GBA1 (0.47) | GBA1AURKARPS6KB1FADS1PARP1 | |
| SCHEMBL1615234 | 0.81 | TAS1R3 (0.48) | GBA1AURKARPS6KB1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101541753-B | 2-aminoquinolines as 5-HT(5A) receptor antagonists | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | claimed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | claimed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| CN-101541753-A | 2-Aminoquinolines as 5-HT(5A) receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | claimed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | claimed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | claimed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |
| CN-101541753-B | 2-aminoquinolines as 5-HT(5A) receptor antagonists | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| CN-101541753-A | 2-Aminoquinolines as 5-HT(5A) receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | GBA1 662/4885AURKA 4689/4885RPS6KB1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.